Zanubrutinib is a BTK inhibitor reported to be effective for B‐cell lymphomas with MYD88 and CD79b mutations, double expression of MYC and BCL2/BCL6, and CD5 expression.33, 34, 35. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.